WALTHAM, Mass.--(BUSINESS WIRE)--The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance to Oscient Pharmaceuticals (Nasdaq: OSCI) for a U.S. patent relating to methods of use of Ramoplanin for the treatment of Clostridium difficile-associated disease (CDAD), a serious form of colitis. Ramoplanin is a glycolipodepsipeptide antibiotic positioned for Phase III development for the potential treatment of CDAD, pending the conclusion of ongoing partnership discussions. A Notice of Allowance is the official notification that the USPTO finds the claimed subject matter allowable and intends to issue the patent pending payment of the issue fee. Given this action, Oscient expects the patent to issue within the next several months.
